Table 2 Intermediate models showing the influence of the different covariates on the vancomycin pharmacokinetic parameters.

From: Population pharmacokinetic modeling and clinical application of vancomycin in Chinese patients hospitalized in intensive care units

 

Model

F change

Basic model

CL = θ1

V = θ2

/

Covariates forCL

DA

CL = θ1 + θ2*DA

V = θ3

5.3 (P = 0.022)

Cr

CL = θ1 + θ2* Cr

V = θ3

93.9 (P = 0.000)

VM

CL = θ1 + θ2* VM

V = θ3

3.7 (P = 0.041)

Burn-S

CL = θ1 + θ2* Burn-S

V = θ3

9.1 (P = 0.003)

TBW

CL = θ1 + θ2* TBW

V = θ3

116.4 (P = 0.000)

CRRT-S

CL = θ1 + θ2* TBW

V = θ3

27.9 (P = 0.000)

Covariates forV

Cr

V = θ1 + θ2* Cr

CL = θ3

104.4 (P = 0.000)

Age

V = θ1 + θ2* Cr

CL = θ3

56.7 (P = 0.000)

VM

CL = θ1 + θ2* VM

V = θ3

3.9 (P = 0.043)

NE

CL = θ1 + θ2* NE

V = θ3

4.0 (P = 0.043)

TBW

V = θ1 + θ2* TBW

CL = θ3

93.8 (P = 0.000)

CRRT-S

V = θ1 + θ2* Cr

CL = θ3

28.8 (P = 0.000)

  1. Increases in the F value (F-change) represent the degree of influence of the addition of the corresponding covariate on CL and V (P < 0.05 represent that addition of the corresponding covariate to the base model has a significant effect on CL and V).
  2. DA dopamine; Cr serum creatinine; VM vancomycin manufacturer; Burn-S burn status; TBW total body weight; CRRT-S continuous renal replacement therapy status; NE noradrenaline.
Back to article page